Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DAT-2645 in BRCA1/2 loss-of-function mutation or HRD-positive advanced/metastatic ovarian cancer
CTR20262136Phase 2Active
- Sponsor
- Danqing Biotech
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DAT-2645 in ovarian cancer, sponsored by Danqing Biotech. Started May 2026; status: active.
02
Drugs
DAT-2645
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on CTR20262136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262136.